


AUTHOR QUERY FORM

	Book: Dynamic Echocardiography Chapter: 09963	Please e-mail your responses and any corrections to: E-mail: k.mannix@elsevier.com
---	--	---

Dear Author,

Any queries or remarks that have arisen during the processing of your manuscript are listed below and are highlighted by flags in the proof. (AU indicates author queries; ED indicates editor queries; and TS/TY indicates typesetter queries.) Please check your proof carefully and answer all AU queries. Mark all corrections and query answers at the appropriate place in the proof using on-screen annotation in the PDF file. For a written tutorial on how to annotate PDFs, click http://www.elsevier.com/_data/assets/pdf_file/0016/203560/Annotating-PDFs-Adobe-Reader-9-X-or-XI.pdf. A video tutorial is also available at <http://www.screencast.com/t/9OIDFhihgE9a>. Alternatively, you may compile them in a separate list and tick off below to indicate that you have answered the query.

Please return your input as instructed by the project manager.

Location in Chapter	Query / remark	
AU:1, page 1	Pls confirm or supply affiliation information for the FM: Itzhak Kronzon, MD, FASE Director, Cardiac Imaging Department Noninvasive Cardiology North Shore LIJ/Lenox Hill Hospital New York, New York Roberto Lang, MD, FASE Muhamed Saric, MD, PhD Associate Professor of Medicine Director, Echocardiography Lab Leon H. Charney Division of Cardiology New York University Langone Medical Center New York, New York	<input type="checkbox"/>
AU:2, page 4	Spelling ok as changed from "straitening" to "straightening"?	<input type="checkbox"/>
AU:3, page 7	Pls. supply pub date	<input type="checkbox"/>
AU:4, page 8	Pls. supply place of publication	<input type="checkbox"/>
AU:5, page 11	Provide specific x-ref here?	<input type="checkbox"/>
AU:6, page 16	Pls confirm or provide affiliation information for the FM: Kathleen Stergiopoulos, MD, PhD, FASE Associate Professor of Clinical Medicine Department of Medicine Stony Brook University Medical Center Stony Brook, New York Fabio Lima, MPH Smadar Kort, MD, FASE Professor of Medicine, Director Cardiovascular Imaging Director Valve Center Department of Medicine Division of Cardiovascular Medicine Stony Brook University Medical Center Stony Brook, New York	<input type="checkbox"/>

AU:7, page 16	Was reference 3 also meant to be cited here?	<input type="checkbox"/>
AU:8, page 18	“Valvuloplasty” in definitions of PMBV earlier in the book. “Valvotomy” OK here?	<input type="checkbox"/>
TS:1, page 10	Please provide the citation.	<input type="checkbox"/>

8 SECTION XVII Mitral Stenosis

17. Pérez-Gómez F, Salvador A, Zumalde J, et al.: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial, *Eur Heart J* 27(8):960-967, 2006 Apr.
18. Inoue K, Owaki T, Nakamura T, et al.: Clinical application of transvenous mitral commissurotomy by a new balloon catheter, *J Thorac Cardiovasc Surg* 87:394-402, 1984.
19. Wilkins GT, Weyman AE, Abascal VM, et al.: Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation, *Br Heart J* 60(4):299-308, 1988.
20. Saric M, Benenstein R: Three-dimensional echocardiographic guidance of percutaneous procedures. In Nanda Navin, editor: *Comprehensive textbook of echocardiography*, 2013, Jaypee Brothers.
21. Starr A, Herr RH, Wood JA: The present status of valve replacement. Special issue on the VII Congress of the International Cardiovascular Society, Philadelphia, *J Cardiovasc Surg* 95-103, 1965.
22. Bonow RO, Carabello BA, Chatterjee K, et al.: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, *J Am Coll Cardiol* 48(3):e1-e148, 2006.

sc0020 **109** Quantification of Mitral Stenosis

Muhamed Saric, MD, PhD, Roberto M. Lang, MD, and Itzhak Kronzon, MD

p0400 Echocardiography is the modality of choice for the diagnosis of mitral stenosis. The joint American Society of Echocardiography and European Association of Echocardiography guidelines for native valvular stenosis feature an exhaustive review of echocardiographic methods for quantitative assessment of mitral stenosis.¹ Full echocardiographic evaluation of mitral stenosis includes the following three sets of parameters: (1) mean diastolic transmitral pressure gradient; (2) mitral valve area (MVA); and (3) secondary changes including measurements of relevant chamber sizes and estimation of right heart pressures. Most modern ultrasound systems contain built-in software packages for determining these parameters. Major methods for quantification of mitral stenosis are presented in Figures 109-1 and 109-2. In most instances, evaluation of mitral stenosis by invasive methods of cardiac catheterization is not necessary unless there is a discrepancy between clinical and echocardiographic findings.

of the exact direction of the transmitral flow. The angle between the interrogating beam and the transmitral jet should be 0 degrees.

Gradient can be assessed by pulsed-wave Doppler with the sample volume at the tips of the leaflets or by continuous-wave Doppler. By tracing the spectral Doppler-derived diastolic transmitral flow velocity envelope and with the use of built-in algorithms available in most modern ultrasound imaging systems, one can obtain the mean MV gradient (see Fig. 109-1, A). To calculate the mean gradient, the system first calculates instantaneous pressure gradients using the simplified Bernoulli equation (see Eq. 109-4, later) and then averages them out:


$$\Delta P = \frac{\sum_{i=0}^n V_i^2}{n} \quad (109-1)$$

where ΔP is the mean diastolic transmitral pressure gradient, V is the instantaneous transmitral velocity, and n is the number of instantaneous gradients measured.

In the presence of atrial fibrillation, mean diastolic gradient should be averaged from multiple (typically five) cardiac cycles. When the mitral valve is normal, there is no significant diastolic transmitral pressure gradient. In severe mitral stenosis, the mean gradient is typically greater than 10 mm Hg; in moderate stenosis it is between 5 and 10 mm Hg, and in mild stenosis it is less than 5 mm Hg. It is important to emphasize that these cutoff values assume a normal transmitral flow (a normal stroke volume and a

s0070 **MEAN PRESSURE GRADIENT MEASUREMENTS**

p0405 Mean diastolic pressure gradient is inversely related to MVA; that is, the more severe the mitral stenosis, the higher the mean diastolic pressure gradient across the mitral valve. This gradient can be easily measured by pulsed- and continuous-wave Doppler.² The best approach for transmitral flow evaluation and gradient determination should be with the transducer at the apex, imaging in four-chamber or two-chamber views. Color flow imaging can be helpful for the assessment



f0040 **Figure 109-1.** Quantitative assessment of mitral stenosis by spectral Doppler. **A**, Assessment of the mean diastolic mitral gradient. This patient has severe mitral stenosis (mean gradient 11 mm Hg at a heart rate of 70 beats per minute). **B**, Mitral valve area by pressure half-time (PHT). This patient has severe mitral stenosis (mitral valve area 0.94 cm²). Note that a 50% drop in initial pressure (from 18 to 9 mm Hg) corresponds to a 70% drop in initial velocity (from 2.1 m/sec to 1.5 m/sec). (See Video 109-1, B, which conceptually corresponds to this panel, albeit in a different patient.) **C**, Mitral valve area by deceleration time (DT). Because DT is approximately 0.29 × PHT, the formula MVA = 220/PHT may be expressed as MVA = 759/DT.




Figure 109-2. Quantitative assessment of mitral stenosis by mitral valve area (MVA) methods. **A**, Mitral valve area by two-dimensional planimetry at mitral leaflet tips in the transthoracic short axis. The patient has mild moderate mitral stenosis (MVA = 1.21 cm²) (see Video 109-2, A). **B**, Mitral valve area by three-dimensional (3D) planimetry in this patient with severe mitral stenosis. The panel demonstrates the LV aspect of the mitral valve. On newer systems, MVA can be planimeted directly on a 3D image (0.6 cm² in this patient). On older systems, a grid is used to calculate MVA. Each rectangle on the grid corresponds to 0.25 cm² (5 × 5 mm) (see Video 109-2b). **C**, Mitral valve area by multiplane reconstruction (MPR) of a 3D transesophageal echocardiography clip. MPR allows for localizing true tips of mitral leaflets; thus this method allows for most accurate assessment of anatomic mitral valve area. **D**, Mitral valve area by proximal isovelocity surface area (PISA) method. Both color and continuous-wave spectral Doppler are required. Note that when the color Doppler baseline is shifted, the aliasing velocity used to calculate MVA is the one in the direction of blood flow (38 cm/sec in this case). This patient has moderate mitral stenosis (MVA = 1.12 cm²). LA, Left atrium; LV, left ventricle; MV, mitral valve; RA, right atrium.

normal heart rate). Mean diastolic gradient is strongly influenced by changes in transmitral flow:

$$\Delta P \approx Flow^2 \quad (109-2)$$

Thus, exercise, fever, anemia, and/or pregnancy may lead to marked increases in transmitral pressure gradients and worsening of patients' symptoms. For instance, during pregnancy, cardiac output may increase 1.7-fold; based on Equation 109-2, this theoretically

translates to a 1.7² or 2.9-fold increase in transmitral pressure gradient.³

Stress testing may provide additional information on hemodynamic significance of mitral stenosis; transmitral pressure gradients and right heart pressures are measured during exercise or dobutamine stress echocardiography. Stress testing in mitral stenosis may be used to assess patients' symptoms or to evaluate for percutaneous mitral balloon valvuloplasty (PMBV). For instance, in asymptomatic patients with moderate or severe mitral stenosis,

TABLE 109-1 Quantitative Assessment of Mitral Stenosis

Parameter	Unit	Normal	Mild MS	Moderate MS	Severe MS	Method	Comments		
Primary determinant of severity	Mitral valve area (MVA)	cm ²	4.0-6.0	>1.5	1.0-1.5	<1.0	Planimetry	Possibly the gold standard MVA underestimated: atrial septal defect or severe aortic regurgitation MVA overestimated: LV diastolic dysfunction with low LV compliance	
							Pressure half-time (PHT)		Typically requires angle correction
							Proximal isovelocity surface area (PISA) Continuity equation		Not applicable with significant concomitant mitral regurgitation
Supportive findings	Mean gradient	mm Hg	Negligible	<5	5-10	>10	Mean gradient = average of 4V ² measurements	Assuming a heart rate of 60-80 bpm. Mean gradient is directly proportional to heart rate and transvalvular flow	
	Pulmonary artery systolic pressure (PASP)	mm Hg	<30	<30	30-50	>50	PASP = 4V ² + RAP	Caveat: A wide range of PASP has been observed for any given MVA	

bpm, Beats per minute; LV, left ventricle; MS, mitral stenosis; RAP, right atrial pressure.

PMBV is indicated when pulmonary artery systolic pressure is greater than 50 mm Hg at rest or greater than 60 mm Hg with exercise, or when there is new-onset atrial fibrillation. PMBV may also be considered in symptomatic patients with mild mitral stenosis (valve area > 1.5 cm²) when pulmonary artery systolic pressure is greater than 60 mm Hg, pulmonary artery wedge pressure is greater than 25 mm Hg, or mean mitral valve gradient is greater than 15 mm Hg during exercise.⁴

Unlike the mean gradient, the peak diastolic mitral gradient is not a good measure of mitral stenosis severity, as it is often markedly influenced by other factors such as the left atrial (LA) compliance and left ventricular (LV) diastolic function.

MITRAL VALVE AREA MEASUREMENTS

Normal MVA in an adult is approximately 4.0 to 6.0 cm². MVA can be calculated using a variety of noninvasive and invasive methods, none of which is considered a true gold standard. Irrespective of the method used, severe mitral stenosis is defined as MVA less than 1.0 cm²; moderate when MVA is between 1.0 and 1.5 cm², and mild when MVA is greater than 1.5 cm². Indexing of MVA for body surface area has not been validated.

The most commonly used invasive method for estimated MVA is based on the Gorlin and Gorlin equation⁵ published in 1951:

$$MVA = \frac{Q}{44.3 * c * \sqrt{\Delta P}} \quad (109-3)$$

where Q is the diastolic transmitral flow rate (in mL/min), c is a constant (0.85 for mitral valve), and ΔP is the mean diastolic transmitral gradient (in mm Hg). This method requires invasive measurements of both the cardiac output and the diastolic transmitral pressure gradient.

Ideally, the gradient should be measured directly as the difference between LV and LA diastolic pressure, typically after a transeptal puncture. However, pulmonary artery wedge pressure is often used in lieu of LA pressure; this typically overestimates the transmitral gradient (and thus the severity of mitral stenosis) compared with direct LA pressure measurements.⁶ Using echocardiography, MVA can either be measured directly (anatomic orifice area) or estimated from Doppler measurements (effective orifice area).

Pressure Half-Time Method

Pressure half-time (PHT) is defined as the length of time required for the maximal early diastolic transmitral gradient to reach half its value (see Fig. 109-1, B, and Video 109-1, B). PHT is inversely related to MVA. PHT is quite short in patients without significant mitral stenosis because the transmitral (LA to LV) diastolic pressure gradient declines rapidly as the pressures in these two chambers quickly equalize. On the other hand, with severe mitral stenosis, the pressure gradient declines very slowly, resulting in a long PHT.

A semiquantitative method for estimating MVA from PHT was originally a cardiac catheterization technique using direct pressure measurements (thus the PHT name).⁷ The technique was later adapted for quantitative MVA assessments from noninvasive Doppler measurements. Historically, spectral Doppler was first used to measure PHT; continuous-wave Doppler is now preferred.

Using the simplified Bernoulli equation:

$$\Delta P = 4 * V^2 \quad (109-4)$$

where ΔP is the transmitral gradient (in mm Hg) and V is the velocity of blood (in m/sec), one can demonstrate that PHT is reached when the initial maximal velocity of blood across the mitral valve during diastole drops to 70% of its initial value. Hatle and colleagues⁸ developed an empirical equation for calculating MVA from PHT:

$$MVA \text{ (cm}^2\text{)} = 220/\text{PHT (msec)} \quad (109-5)$$

Thus, in a patient with PHT of 220 msec, the MVA is calculated to be 1.0 cm². Because of its simplicity, PHT is the most commonly used Doppler technique for estimating MVA. For patients in atrial fibrillation, an average value of PHT derived from (typically) five cardiac cycles should be used. Short cardiac cycles should be avoided as they may be too brief for the pressure to drop to half its value. In some instances, the spectral Doppler velocity decay has not one but two slopes; this may be seen in patients with both mitral stenosis and mitral regurgitation. In such instances the initial slope (occurring typically within first 300 msec of transmitral flow) can be ignored; subsequent (mid-diastolic) slope should then be used to measure PHT.⁹

Occasionally, the PHT method may not accurately calculate MVA (e.g., when the changes in LA and/or LV pressures are

independent of mitral stenosis, when the initial transmitral pressure gradient is very high, or after PMBV).¹⁰ The PHT method overestimates MVA in patients with large atrial septal defects, significant aortic regurgitation, or LV diastolic dysfunction, and/or when the initial transmitral pressure gradient is very high. In patients with both mitral stenosis and atrial septal defect (referred to as Lutembacher syndrome),¹¹ a significant left-to-right shunt decompresses the leaflet atrium, decreases the transmitral gradient, and shortens the PHT, leading to overestimation of MVA. Significant aortic regurgitation and/or LV diastolic dysfunction may lead to increased LV diastolic pressure; this in turn diminishes the transmitral gradient, shortens the PHT, and leads to overestimation of MVA.

p0490 In patients with LV diastolic dysfunction (who tend to be elderly), abnormal LV relaxation leads to either prolongation or shortening of PHT independent of mitral stenosis. Abnormal LV relaxation prolongs PHT (leading to underestimation of MVA), whereas abnormal LV compliance shortens PHT (leading to overestimation of MVA). Thus, the PHT method should be used with caution in elderly patients with mitral stenosis. One should not use PHT to estimate MVA after PMBV because LV diastolic pressure may rise significantly as the relatively noncompliant left ventricle experiences an abrupt increase in transmitral flow after balloon-mediated relief of mitral stenosis.¹² When PHT is unavailable, one can use mitral deceleration time instead.

s0085 Mitral Deceleration Time Method

p0495 The deceleration time (DT) of the mitral E wave is defined as the length of time from the peak velocity of early diastolic mitral flow (E wave Vmax) to the end of antegrade transmitral flow (V=0). Like PHT, the length of DT is also inversely related to the MVA (i.e., longer DT indicates smaller MVA). Because DT is related to PHT according to

$$\text{PHT (msec)} = 0.29 \times \text{DT (msec)} \quad (109-6)$$

p0500 MVA can then be calculated from DT (see Fig. 109-1, C) from the following equation:

$$\text{MVA (cm}^2\text{)} = 759/\text{DT (msec)} \quad (109-7)$$

s0090 Mitral Valve Area by Planimetry

p0505 Anatomic MVA can be measured by either two-dimensional (2D) or three-dimensional (3D) planimetry; measurements should be done in mid-diastole at leaflet tips. For 2D planimetry, a short axis at the level of the mitral leaflet tips is obtained and a mid-diastolic frame with maximal opening of mitral leaflets is chosen (see Figure 109-2, A, and Video 109-2, A). MVA is then planimeted using standard ultrasound-system quantitative tools. The major shortcoming of 2D planimetry is its inability to accurately determine the location of true leaflet tips as they are often eccentrically located outside the short-axis plane.

p0510 3D planimetry overcomes these limitations and is now considered the echocardiographic gold standard for calculation of MVA.¹³ 3D planimetry may be done using a variety of methods such as multiplane reconstruction, on-image planimetry, or estimation of MVA using a rectangular reference grid (see Fig. 109-2, B and C, and Video 109-2, B).

s0095 Mitral Valve Area by Doppler Techniques

p0515 Doppler methods for calculated MVA include pressure half-time, continuity equation, and proximal isovelocity surface area (PISA).

Mitral Valve Area by Continuity-Equation Method

109

The continuity-equation method assumes that a stroke volume (SV₁) across one orifice equals the stroke volume (SV₂) across another orifice in the same closed circulatory system. In the absence of significant mitral or aortic regurgitation, *diastolic* stroke volume across the mitral valve (MV) is equal to the *systolic* stroke volume across the LV outflow tract (LVOT):

$$\text{SV}_{\text{MV}} = \text{SV}_{\text{LVOT}} \quad (109-8)$$

Using echocardiography, SV across any orifice can be calculated as a product of the orifice area and the flow velocity time integral (VTI):

$$\text{LVOT Area} \times \text{LVOT VTI} = \text{MVA} \times \text{MV VTI} \quad (109-9)$$

Solving for MVA, one obtains the following equation: p0530

$$\text{MVA} = \text{LVOT Area} \times \frac{\text{LVOT VTI}}{\text{MV VTI}} \quad (109-10)$$

Systolic LVOT VTI and diastolic MV VTI are measure by p0535 pulsed-wave and continuous-wave Doppler, respectively. LVOT area is typically calculated after measuring the systolic LVOT diameter (d) in the parasternal long-axis view and assuming a circular LVOT shape:

$$\text{LVOT Area} = \pi \times \left(\frac{d}{2}\right)^2 \quad (109-11)$$

Thus, using the continuity equation, MVA can be calculated as p0540 follows:

$$\text{MVA} = \pi \times \left(\frac{d}{2}\right)^2 \times \frac{\text{LVOT VTI}}{\text{MV VTI}} \quad (109-12)$$

Aside from significant mitral and aortic regurgitation, a miscalculation of LVOT area is the major limitation of estimating MVA by the continuity-equation method. This occurs because of either mismeasurement of LVOT diameter or frequent noncircularity of LVOT area. In general, the continuity-equation method for estimating MVA should not be used in atrial fibrillation. p0545

Mitral Valve Area by Proximal IsovLOCITY Surface Area Method

s0105

The PISA method is also based on the continuity principle. The method is described in detail in another chapter. Briefly, blood flow progressively accelerates as it approaches an orifice (such as a stenotic mitral valve). This then ideally leads to formation of a series of hemispheric isovelocity surfaces whose areas become progressively smaller and their velocities progressively faster as the flow approaches the orifice. p0550

According to the continuity principle, the amount of flow at the level any of the hemispheres should equal the flow across the stenotic mitral valve.¹⁴ Using Doppler methods and the PISA method, MVA area can be calculated using the following formula: p0555

$$\text{MVA} = 2 \times \pi \times r^2 \times \frac{\text{Valias}}{\text{Vmax}} \quad (109-13)$$

where *r* is the radius of the hemisphere (PISA radius) in centimeters, *Valias* is the aliasing velocity of color Doppler flow (in cm/sec), and *Vmax* is the maximal transmitral velocity (also in cm/sec).

The basic PISA method assumes that the orifice is a planar structure (that is, at a 180-degree angle). Typically, this is not the case with mitral stenosis, where the orifice is funnel shaped (that is, at an angle that is less than 180 degrees). Consequently, p0565

as the flow approaches a stenosed mitral orifice, PISA shells are not full hemispheres but partial hemispheres. Thus, to properly calculate MVA by the PISA method, Equation 109-13 needs to be modified to include an angle correction factor:

$$MVA = 2 * \pi * r^2 * \frac{Valias}{Vmax} * \frac{\vartheta}{180} \quad (109-14)$$

where ϑ is the angle between the two mitral leaflets in diastole (see Fig. 109-2, D).

p0575 The PISA method for MVA calculation is valid even in the presence of concomitant mitral regurgitation because increased diastolic flow due to mitral regurgitation will equally affect the flow at the level of both isovelocity hemispheres and mitral leaflet tips.

s0110 Semiquantitative Mitral Valve Area Assessment by M-Mode Echocardiography

p0580 M-mode echocardiography has high sensitivity and specificity for the diagnosis of mitral stenosis. It may demonstrate thickened, calcified, and abnormally moving mitral leaflets. The smaller posterior leaflet, which is fused with the larger anterior leaflet, demonstrates an abnormal anterior motion on M-mode during diastole.

p0585 The severity of mitral stenosis can be roughly estimated from the EF slope of the anterior leaflet. In mitral stenosis, after initial opening (E point), the anterior leaflet does not travel posteriorly toward the closing position fast enough because the elevated trans-mitral pressure gradient maintains the valve in the opened position longer than normal. The more severe the mitral stenosis, the flatter the EF slope.

p0590 Similarly, the rate of emptying of the left atrium visualized by M-mode can be used to roughly estimate the severity of mitral stenosis. Normally, most atrial emptying (or LV filling) occurs promptly in early diastole, whereas in mitral stenosis LA emptying is gradual and lasts throughout diastole.

s0115 SECONDARY CHANGES DUE TO MITRAL STENOSIS

p0595 Mitral stenosis may lead to chronic LA pressure overload, potentially resulting in LA enlargement, pulmonary hypertension, right heart dilation, and functional tricuspid regurgitation. Techniques for estimating chamber sizes and right heart pressures are discussed in other chapters.

p0600 In patients with mitral stenosis, a wide range of pulmonary artery pressures has been observed for a given MVA. Elevated LA pressure leading to pulmonary venous congestion is the primary reason for pulmonary hypertension in patients with mitral stenosis. For unclear reasons, a subset of patients may also develop pulmonary arterial hypertension, which, unlike pulmonary venous hypertension, may not resolve after percutaneous or surgical correction of mitral stenosis.

p0605 Noninvasive assessment of pulmonary vascular resistance (PVR) by echocardiography may help differentiate between pure pulmonary venous hypertension (normal PVR) and superimposed pulmonary arterial hypertension (high PVR). In general, PVR is directly related to transpulmonary pressure gradient and inversely related to the transpulmonary blood flow. Noninvasively, PVR can be calculated from spectral Doppler tracings of tricuspid regurgitant jet and the flow across the right ventricular outflow tract using the so-called Abbas¹⁵ equation:

$$PVR = 0.16 + 10 * \frac{Vmax\ of\ TR\ Jet}{RVOT\ VTI} \quad (109-15)$$

where $Vmax$ of the tricuspid regurgitant (TR) jet is in meters per second, right ventricular outflow tract (RVOT) VTI in centimeters,

and PVR in Wood units. In principle, echocardiographic PVR measurements should be confirmed by invasive methods.

The routine echocardiographic evaluation of MS does not require transesophageal echocardiography (TEE). However, TEE should be considered when the image quality and Doppler information are suboptimal or do not correlate with the clinical impression. TEE is also useful in the evaluation of complications of mitral stenosis, such as LA clot or endocarditis. TEE is also frequently used before and during MV balloon valvuloplasty.¹⁶

SUMMARY

The American Society of Echocardiography and European Association of Echocardiography recommend that mean diastolic gradient and MVA determination by planimetry and PHT should be performed in all patients with mitral stenosis (Level 1 recommendation). In selected patients, MVA may also be determined by continuity-equation and/or PISA methods (Level 2 recommendation). Stress testing for mitral stenosis is also a Level 2 recommendation. In the presence of significant mitral regurgitation, all the foregoing methods for calculating MVA are valid except for continuity equation. Details of mitral valve anatomy and secondary changes due to mitral stenosis should also be reported for all echocardiographic exams as discussed in relevant chapters of this book.

Please access ExpertConsult to view the corresponding videos for this chapter.

REFERENCES

- Baumgartner H, Hung J, Bermejo J, et al.: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice, *J Am Soc Echocardiogr* 22(1):1-23, 2009, erratum in *J Am Soc Echocardiogr* 2009;22(5):442.
- Hatle L, Brubakk A, Tromsdal A, Angelsen B: Noninvasive assessment of pressure drop in mitral stenosis by Doppler ultrasound, *Br Heart J* 40(2):131-140, 1978.
- Carabello BA: Modern management of mitral stenosis, *Circulation* 112(3):432-437, 2005.
- Bonow RO, Carabello BA, Kanu C, et al.: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, *Circulation* 114(5):e84-e231, 2006.
- Gorlin R, Gorlin SG: Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I, *Am Heart J* 41(1):1-29, 1951.
- Nishimura RA, Rihal CS, Tajik AJ, Holmes Jr DR: Accurate measurement of the transmitral gradient in patients with mitral stenosis: a simultaneous catheterization and Doppler echocardiographic study, *J Am Coll Cardiol* 24(1):152-158, 1994.
- Libanoff AJ, Rodbard S: Atrioventricular pressure half-time. Measure of mitral valve orifice area, *Circulation* 38(1):144-150, 1968.
- Hatle L, Angelsen B: *Doppler ultrasound in cardiology: physical principles and clinical applications*, Philadelphia, 1985, Lea and Febiger, 118.
- Gonzalez MA, Child JS, Krivokapich J: Comparison of two-dimensional and Doppler echocardiography and intracardiac hemodynamics for quantification of mitral stenosis, *Am J Cardiol* 60(4):327-332, 1987.
- Thomas JD, Weyman AE: Mitral pressure half-time: a clinical tool in search of theoretical justification, *J Am Coll Cardiol* 10:923-929, 1987.
- Lutembacher R: De la sténose mitrale avec communication interauriculaire, *Arch Mal Coeur Vaiss* 9:237-250, 1916.
- Thomas JD, Wilkins GT, Choong CY, et al.: Inaccuracy of mitral pressure half-time immediately after percutaneous mitral valvotomy. Dependence on transmitral gradient and left atrial and ventricular compliance, *Circulation* 78(4):980-993, 1988.
- Schlosshan D, Aggarwal G, Mathur G, et al.: Real-time 3D transesophageal echocardiography for the evaluation of rheumatic mitral stenosis, *JACC Cardiovasc Imaging* 4(6):580-588, 2011.
- Rodriguez L, Thomas JD, Monterroso V, et al.: Validation of the proximal flow convergence method. Calculation of orifice area in patients with mitral stenosis, *Circulation* 88(3):1157-1165, 1993.
- Abbas AE, Fortuin FD, Schiller NB, et al.: A simple method for noninvasive estimation of pulmonary vascular resistance, *J Am Coll Cardiol* 41(6):1021-1027, 2003.
- Perk G, Ruiz C, Saric M, Kronzon I: Real-time three-dimensional transesophageal echocardiography in transcatheter, catheter-based procedures for repair of structural heart diseases, *Curr Cardiovasc Imaging Rep* 2(5):363-374, 2009.